FollowMyHealth Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.
Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM
Neurology. 2017 Nov 8; pii: 10.1212/WNL.0000000000004717. doi: 10.1212/WNL.0000000000004717.

PMID:
    29117955
    [PubMed - as supplied by publisher]
Related citations


Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Andrew RJ, Fernandez CG, Stanley M, Jiang H, Nguyen P, Rice RC, Buggia-Prévot V, De Rossi P, Vetrivel KS, Lamb R, Argemi A, Allaert ES, Rathbun EM, Krause SV, Wagner SL, Parent AT, Holtzman DM, Thinakaran G
Proc Natl Acad Sci U S A. 2017 Nov 7; 114(45)E9665-E9674. doi: 10.1073/pnas.1708568114.

PMID:
    29078331
    [PubMed - in process]
Related citations


TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.
Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM
Proc Natl Acad Sci U S A. 2017 Oct 24; 114(43)11524-11529. doi: 10.1073/pnas.1710311114.

PMID:
    29073081
    [PubMed - in process]
Related citations


NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia.
Galindo R, Banks Greenberg M, Araki T, Sasaki Y, Mehta N, Milbrandt J, Holtzman DM
Ann Clin Transl Neurol. 2017 Oct; 4(10)722-738. doi: 10.1002/acn3.450.

PMID:
    29046881
    [PubMed]
Related citations


Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal.
Kang SS, Kurti A, Baker KE, Liu CC, Colonna M, Ulrich JD, Holtzman DM, Bu G, Fryer JD
Hum Mol Genet. 2017 Oct 11; doi: 10.1093/hmg/ddx366.

PMID:
    29040522
    [PubMed - as supplied by publisher]
Related citations


ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Alzheimer’s Disease Neuroimaging Initiative., Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM
Nature. 2017 Sep 28; 549(7673)523-527. doi: 10.1038/nature24016.

PMID:
    28959956
    [PubMed - in process]
Related citations


Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.
Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM, Dominantly Inherited Alzheimer Network (DIAN)., Disease Neuroimaging Initiative (ADNI)., NIA-LOAD family study., Harari O
Alzheimers Dement. 2017 Sep 21; pii: S1552-5260(17)33708-1. doi: 10.1016/j.jalz.2017.08.013.

PMID:
    28943286
    [PubMed - as supplied by publisher]
Related citations


The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O
Immunity. 2017 Sep 19; 47(3)566-581.e9. doi: 10.1016/j.immuni.2017.08.008.

PMID:
    28930663
    [PubMed - indexed for MEDLINE]
Related citations


Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.
Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM
Brain. 2017 Aug 1; 140(8)2104-2111. doi: 10.1093/brain/awx148.

PMID:
    28899014
    [PubMed - indexed for MEDLINE]
Related citations


TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M
Cell. 2017 Aug 10; 170(4)649-663.e13. doi: 10.1016/j.cell.2017.07.023.

PMID:
    28802038
    [PubMed - indexed for MEDLINE]
Related citations


Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.
Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ
Alzheimers Dement. 2017 Aug; 13(8)841-849. doi: 10.1016/j.jalz.2017.06.2266.

PMID:
    28734653
    [PubMed - in process]
Related citations


Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.
Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM
Alzheimers Dement. 2017 Jul 12; pii: S1552-5260(17)32516-5. doi: 10.1016/j.jalz.2017.06.2264.

PMID:
    28710906
    [PubMed - as supplied by publisher]
Related citations


Glial contributions to neurodegeneration in tauopathies.
Leyns CEG, Holtzman DM
Mol Neurodegener. 2017 Jun 29; 12(1)50. doi: 10.1186/s13024-017-0192-x.

PMID:
    28662669
    [PubMed - in process]
Related citations


Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.
Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM
J Exp Med. 2017 Jul 3; 214(7)2163. doi: 10.1084/jem.2016212505192017c.

PMID:
    28536241
    [PubMed - in process]
Related citations


Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.
Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM
Neurobiol Aging. 2017 Aug; 5625-32. doi: 10.1016/j.neurobiolaging.2017.04.004.

PMID:
    28482211
    [PubMed - in process]
Related citations


Diurnal oscillation of CSF Aβ and other AD biomarkers.
Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ
Mol Neurodegener. 2017 May 8; 12(1)36. doi: 10.1186/s13024-017-0161-4.

PMID:
    28478762
    [PubMed - in process]
Related citations


Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.
Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM
J Alzheimers Dis. 2017; 58(3)675-680. doi: 10.3233/JAD-170067.

PMID:
    28453487
    [PubMed - in process]
Related citations


Preclinical Alzheimer's disease and longitudinal driving decline.
Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC
Alzheimers Dement (N Y). 2017 Jan; 3(1)74-82. doi: 10.1016/j.trci.2016.11.006.

PMID:
    28435853
    [PubMed]
Related citations


Elucidating the Role of TREM2 in Alzheimer's Disease.
Ulrich JD, Ulland TK, Colonna M, Holtzman DM
Neuron. 2017 Apr 19; 94(2)237-248. doi: 10.1016/j.neuron.2017.02.042.

PMID:
    28426958
    [PubMed - indexed for MEDLINE]
Related citations


Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.
Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, Braunstein J, Robinson G, Keyser J, Roh J, Knapik SS, Hu Y, Holtzman DM
Sci Transl Med. 2017 Apr 19; 9(386)pii: eaal2029. doi: 10.1126/scitranslmed.aal2029.

PMID:
    28424326
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2016.

Company Name: C2N Diagnostics

Royalties: > $1M

Equity: Yes

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2017


Company Name: Neurophage

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2017


Company Name: Denali

Royalties: $10,001 - $25,000

Equity: No

Consulting/Advisory Board: $1,000 - $10,000

Speaker Fees:

Reporting Date: May 01, 2017

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.